Compare BigBearai Holdings Inc (BBAI) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs Becton Dickinson and Co — how do they compare? BigBearai Holdings Inc trades at $3.2 (market cap $1.48B), while Becton Dickinson and Co trades at $156.39 (market cap $41.51B). The key difference: Becton Dickinson and Co is far larger — about 28× BigBearai Holdings Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while BigBearai Holdings Inc pays none. Which is the better fit depends on your goals.
| BBAI | BDX | |
|---|---|---|
Market Cap | $1.48B | $41.51B |
Sector | Technology | Health |
52-Week High | $8.91 | $185.39 |
52-Week Low | $3.05 | $135.49 |
Enterprise Value | $1.16B | $57.97B |
Dividend Yield | — | 2.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBAI trades at $3.08, down 5.81% in the past 24 hours, with a bearish technical signal from moving averages. The company reported revenue of $127.67M in 2025 but a net loss of $293.91M, reflecting a negative net margin of -226.69%. Recent news highlights AI growth opportunities in defense and airport security, yet profitability challenges persist.
Outlook remains cautious due to ongoing losses and negative cash flow from operations. Investment opportunities include backlog growth and debt reduction, but risks include high SG&A expenses and reliance on government contracts. Analyst consensus is mixed with 75% hold ratings, indicating uncertainty about near-term performance.
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
